CN111849887A - Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof - Google Patents
Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof Download PDFInfo
- Publication number
- CN111849887A CN111849887A CN202010777925.2A CN202010777925A CN111849887A CN 111849887 A CN111849887 A CN 111849887A CN 202010777925 A CN202010777925 A CN 202010777925A CN 111849887 A CN111849887 A CN 111849887A
- Authority
- CN
- China
- Prior art keywords
- fat
- stem cells
- svf
- dimensional gel
- adipose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000001879 gelation Methods 0.000 title description 2
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 36
- 210000001519 tissue Anatomy 0.000 claims abstract description 32
- 238000004140 cleaning Methods 0.000 claims abstract description 23
- 230000029087 digestion Effects 0.000 claims abstract description 19
- 239000002244 precipitate Substances 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 12
- 239000006228 supernatant Substances 0.000 claims abstract description 12
- 230000001079 digestive effect Effects 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 102000004142 Trypsin Human genes 0.000 claims abstract description 6
- 108090000631 Trypsin Proteins 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 238000012216 screening Methods 0.000 claims abstract description 6
- 238000010008 shearing Methods 0.000 claims abstract description 6
- 239000012588 trypsin Substances 0.000 claims abstract description 6
- 102000029816 Collagenase Human genes 0.000 claims description 10
- 108060005980 Collagenase Proteins 0.000 claims description 10
- 229960002424 collagenase Drugs 0.000 claims description 10
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 7
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 7
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 7
- 229960003942 amphotericin b Drugs 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 210000000579 abdominal fat Anatomy 0.000 claims description 3
- 210000000689 upper leg Anatomy 0.000 claims description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- 230000006676 mitochondrial damage Effects 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002676 facial rejuvenation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a preparation method of autologous fat three-dimensional gel and SVF stem cells thereof, which comprises the following steps: 1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles; 2) adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate; 3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain autologous fat three-dimensional gel and SVF stem cells thereof; the adipose-derived mesenchymal stem cells obtained by the method have high yield, high purity and good activity, and the problems of low extraction rate, low purity and the like of the existing method for obtaining adipose-derived mesenchymal stem cells are solved.
Description
[ technical field ]
The invention belongs to the technical field of biology, and particularly relates to a preparation method and application of autologous fat three-dimensional gel and SVF stem cells thereof.
[ background art ]
The adipose-derived mesenchymal stem cell is a stem cell with the multipotentiality of multi-way differentiation and is separated from adipose tissues. In recent years, adipose-derived stem cells have become one of the most popular stem cells for tissue engineering and regenerative medicine. The autologous adipose-derived stem cells have wide sources, can secrete a large amount of growth factors such as epidermis, endothelium, blood vessels, fibrillization and the like, can promote the synthesis of human collagen, increase the blood vessels, are easy to survive, change the texture of human skin, reduce facial spots, fade facial wrinkles and improve facial depression, and thus, the change of facial rejuvenation is achieved.
Adipose tissues contain a cell with the potential of multidirectional differentiation, namely adipose tissue vascular stromal cells (SVF), wherein the SVF comprises adipose Mesenchymal Stem Cells (MSC), the biological properties of the SVF are similar to those of bone marrow mesenchymal stem cells, and the SVF can differentiate towards various cells such as fat, bone, cartilage, muscle endothelium, hematopoiesis, liver, pancreatic islet, nerve and the like. The fat tissue has rich storage in human body, easy acquisition and small wound. The amount of adipose tissue is much higher than the amount of bone marrow tissue for the same mass or volume of adipose tissue and bone marrow tissue. Therefore, the mesenchymal stem cells can replace a part of bone marrow mesenchymal stem cells, and have wider clinical application prospect. The adipose-derived mesenchymal stem cells are generally obtained by extracting human adipose tissues, and the applicable adipose-derived mesenchymal stem cells can be obtained only by performing separation treatment after the adipose tissues are extracted, but the existing treatment method has low extraction rate and low purity and activity of the obtained cells.
[ summary of the invention ]
The invention aims to solve the defects and provide a preparation method of autologous adipose three-dimensional gel and SVF stem cells thereof, wherein the obtained adipose-derived mesenchymal stem cells have high yield, high purity and good activity, and the problems of low extraction rate, low purity and the like of the conventional method for obtaining adipose-derived mesenchymal stem cells are solved.
In order to realize the purpose, the preparation method of the autologous fat three-dimensional gel and the SVF stem cells thereof comprises the following steps:
1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles;
2) adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate;
3) and (3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain the autologous fat three-dimensional gel and the SVF stem cells thereof.
Further, in the step 1), the tissue washing solution comprises physiological saline, amphotericin B, gentamicin sulfate and erythrocyte lysate.
Further, in step 1), the source of the autologous adipose tissue includes, but is not limited to, infrapatellar fat pad in the joint, medial thigh adipose tissue near the surgical joint site, or abdominal fat.
Further, in step 2), the fat tissue digestive juice comprises dnase, collagenase type I and collagenase type iii.
Further, the step 3) is followed by a culturing step, specifically, the autologous fat three-dimensional gel obtained in the step 3) and the SVF stem cells thereof are added into a cell culture solution and placed in an incubator for standing culture, the culturing condition is 37 ℃, the culturing time is 5% CO2, and the culturing time is 7-14 days.
Furthermore, the invention also provides an application of the autologous fat three-dimensional gel and SVF stem cells thereof as active ingredients in preparing medicines for improving mitochondrial damage of myocardial cells.
Compared with the prior art, the invention provides the autologous fat three-dimensional gel and the preparation method of the SVF stem cells thereof, which can fully digest adipose tissues and obtain rich nucleated cells by processing the adipose tissues through digestion, cleaning and the like, so that the obtained adipose mesenchymal stem cells have high yield, high purity and good activity, are favorable for clinical application, and solve the problems of low extraction rate, low purity and the like of the existing method for obtaining adipose mesenchymal stem cells.
[ detailed description of the invention ]
The invention is further illustrated below with reference to specific examples:
example 1:
a preparation method of autologous fat three-dimensional gel and SVF stem cells thereof comprises the following steps:
1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles; the tissue cleaning fluid comprises normal saline, amphotericin B, gentamicin sulfate and erythrocyte lysate;
2) adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate; the fat tissue digestive fluid comprises the following components in concentration: 0.06-0.07 mg/mL of DNase, 0.3-0.45 mg/mL of collagenase type I and 0.5-0.65 mg/mL of collagenase type III, wherein a solvent adopts a DMEM medium containing double antibodies; the double antibodies in the DMEM medium containing the double antibodies are 0.6-1.2 mug/mL gentamicin sulfate and 0.6-1.2 mug/mL amphotericin B.
3) And (3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain the autologous fat three-dimensional gel and the SVF stem cells thereof.
The autologous fat three-dimensional gel and the SVF stem cells thereof can be used as active ingredients to prepare medicines for improving the mitochondrial injury of myocardial cells.
Example 2:
a preparation method of autologous fat three-dimensional gel and SVF stem cells thereof comprises the following steps:
1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles; the preparation method of the tissue cleaning fluid comprises the following steps: uniformly mixing normal saline, gentamicin sulfate, amphotericin B and erythrocyte lysate, wherein the concentration of gentamicin sulfate is 20-24 mug/mL, the concentration of amphotericin B is 12.5-14 mug/mL, and the erythrocyte lysate accounts for 53-55% of the total volume.
2) Adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate; the fat tissue digestive juice comprises DNA enzyme, collagenase type I and collagenase type III;
3) and (3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain the autologous fat three-dimensional gel and the SVF stem cells thereof.
Example 3:
a preparation method of autologous fat three-dimensional gel and SVF stem cells thereof comprises the following steps:
1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles; the tissue cleaning fluid comprises normal saline, amphotericin B, gentamicin sulfate and erythrocyte lysate; sources of autologous adipose tissue include, but are not limited to, intra-articular infrapatellar fat pads, medial thigh adipose tissue near the surgical joint site, or abdominal fat;
2) adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate; the fat tissue digestive juice comprises DNA enzyme, collagenase type I and collagenase type III;
3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain autologous fat three-dimensional gel and SVF stem cells thereof;
4) adding the autologous fat three-dimensional gel obtained in the step 3) and the SVF stem cells thereof into a cell culture solution, placing the cell culture solution into an incubator for standing culture, wherein the culture condition is 37 ℃ and 5% CO2 incubator, and the culture time is 7-14 days.
The autologous fat three-dimensional gel and the SVF stem cells thereof can be used as active ingredients to prepare medicines for improving the mitochondrial injury of myocardial cells.
The present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents and are included in the scope of the present invention.
Claims (6)
1. The preparation method of the autologous fat three-dimensional gel and the SVF stem cells thereof is characterized by comprising the following steps:
1) cleaning the collected adipose tissues by using a tissue cleaning solution until no blood residue exists, centrifuging the cleaned adipose tissues, removing supernatant, and shearing the cleaned adipose tissues to obtain fat particles;
2) adding fat tissue digestive juice into the fat particles obtained in the step 1) for primary digestion, adding trypsin for secondary digestion, centrifuging to remove supernatant after digestion is completed, and collecting precipitate;
3) and (3) cleaning the precipitate obtained in the step 3) by using a PBS solution, re-suspending the precipitate by using normal saline, screening to remove large tissues, and centrifuging to obtain the autologous fat three-dimensional gel and the SVF stem cells thereof.
2. The method for preparing autologous fat three-dimensional gel and SVF stem cells thereof according to claim 1, wherein: in the step 1), the tissue cleaning solution comprises normal saline, amphotericin B, gentamicin sulfate and erythrocyte lysate.
3. The method for preparing autologous fat three-dimensional gel and SVF stem cells thereof according to claim 1, wherein: in step 1), the source of the autologous adipose tissue includes, but is not limited to, infrapatellar fat pad in joints, medial thigh adipose tissue near surgical joint sites or abdominal fat.
4. The method for preparing autologous fat three-dimensional gel and SVF stem cells thereof according to claim 1, wherein: in step 2), the fat tissue digestive juice comprises DNase, collagenase type I and collagenase type III.
5. The method for preparing autologous fat three-dimensional gel and SVF stem cells thereof according to claim 1, wherein: and 3) a culture step is further included after the step 3), specifically, the autologous fat three-dimensional gel obtained in the step 3) and the SVF stem cells thereof are added into a cell culture solution and placed in an incubator for standing culture, the culture conditions are 37 ℃ and 5% CO2 incubator, and the culture time is 7-14 days.
6. The autologous fat three-dimensional gel and SVF stem cells thereof according to any of claims 1 to 5, as active ingredients for use in improving mitochondrial damage of cardiomyocytes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010777925.2A CN111849887A (en) | 2020-08-05 | 2020-08-05 | Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010777925.2A CN111849887A (en) | 2020-08-05 | 2020-08-05 | Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111849887A true CN111849887A (en) | 2020-10-30 |
Family
ID=72971367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010777925.2A Pending CN111849887A (en) | 2020-08-05 | 2020-08-05 | Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111849887A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113416694A (en) * | 2021-07-21 | 2021-09-21 | 江苏瑞思坦生物科技有限公司 | Method for efficiently obtaining adipose-derived mesenchymal stem cells from trace fat |
| CN114832016A (en) * | 2022-04-19 | 2022-08-02 | 芙普瑞生物细胞科学(苏州)有限公司 | Adipose SVF cell preparation and application thereof |
-
2020
- 2020-08-05 CN CN202010777925.2A patent/CN111849887A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113416694A (en) * | 2021-07-21 | 2021-09-21 | 江苏瑞思坦生物科技有限公司 | Method for efficiently obtaining adipose-derived mesenchymal stem cells from trace fat |
| CN114832016A (en) * | 2022-04-19 | 2022-08-02 | 芙普瑞生物细胞科学(苏州)有限公司 | Adipose SVF cell preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108004207B (en) | Method for obtaining large amount of adipose mesenchymal stem cells from fat | |
| CN107858329B (en) | Method for separating adipose-derived mesenchymal stem cells from fat and test solution used in method | |
| CN110438072A (en) | The preparation method of fat mesenchymal stem cell | |
| CN105238751A (en) | Umbilical cord tissue mesenchymal stem cell isolated culture method | |
| CN113564111B (en) | Method for culturing umbilical cord-derived mesenchymal stem cells in low-oxygen mode | |
| CN111849887A (en) | Autologous fat three-dimensional gel and preparation method and application of SVF stem cells thereof | |
| CN103223194A (en) | Cartilage graft for cartilage injury repair and preparation method thereof | |
| CN112481202B (en) | Method for serum-free separation culture of umbilical cord mesenchymal stem cells by using platelet lysate | |
| CN111973632B (en) | Stem cell preparation for treating diabetes and preparation method thereof | |
| CN111346051A (en) | Preparation method of umbilical cord mesenchymal stem cell injection for treating cerebral infarction | |
| CN102965337A (en) | Method for separating and extracting human subcutaneous adipose-derived mesenchymal stem cells and special culture medium for extraction | |
| CN113151165B (en) | Culture medium and culture method for human umbilical cord mesenchymal stem cell amplification | |
| CN101705209A (en) | Method for separating heart stem cells from brown fat and splitting cardioblast | |
| CN112300986B (en) | Method for preparing adipose-derived mesenchymal stem cells by serum-free medium | |
| CN110693911A (en) | Menstrual blood-derived endometrial stem cell preparation and preparation method and application thereof | |
| CN112716976A (en) | Nano composite hydrogel containing umbilical cord mesenchymal stem cells and preparation method and application thereof | |
| CN110643572A (en) | Separation and purification method of umbilical cord mesenchymal stem cells | |
| CN110016461A (en) | A kind of cartilage cell's amplification in vitro method | |
| CN112280735B (en) | Umbilical cord-derived mesenchymal stem cells and preparation method and application thereof | |
| CN104818243A (en) | Separation method of placenta-derived fetal stem cells | |
| CN112522193B (en) | Application of serum-free culture medium in separation and passage of adipose-derived mesenchymal stem cells | |
| CN111281888A (en) | Human umbilical cord mesenchymal stem cell injection for treating femoral head necrosis | |
| CN104818246B (en) | A kind of isolated culture method of rabbit fat stem cell | |
| CN103816183A (en) | Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis | |
| EP2558568B1 (en) | Method for obtaining a population of stromal progenitor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201030 |
|
| WD01 | Invention patent application deemed withdrawn after publication |